Mazen Animal Health Receives Key Patent for Orally Delivered Animal Vaccines


Patent Covers PEDV Sequence Expression in Plants and Plant-Produced Vaccines.

Mazen Animal Health Inc., a pioneer animal health company developing novel
maize-based vaccines announced today it has been issued a patent for its transformative technology to  produce orally delivered animal vaccines. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent US-11566255-B2, “Expression of PEDV Sequences in Plants and Plant Produced Vaccine for Same” on January 31, 2023. This patent covers foundational technology for the company’s first vaccine product,  which is anticipated for launch in 2024.

Porcine Epidemic Diarrhea Virus (PEDV) is a virus of widespread concern, causing diarrhea, vomiting and  severe dehydration. The disease has a death rate from 80%-100% in infected piglets. PEDV prevention in  neonatal pigs is challenging as the virus is highly infectious and able to survive in the environment even with  strict sanitation practices.

Mazen’s first product will provide effective, lactogenic immunity to piglets through orally delivered maizeproduced PEDV antigens dosed to the sows during gestation. “This initial patent marks a major milestone for  the company, allowing us to protect our products as we move forward with our game-changing, unique  approach to animal vaccines,” said Jennifer Filbey, PhD, CEO of Mazen. “We anticipate this is the first in many
patents to come.”

Mazen’s PEDV patent builds on an established portfolio covering the underlying platform technology developed by John Howard, PhD, one of the company’s founders. Mazen holds an exclusive license to the  platform for use in the field of animal health.